证券代码：002275 证券简称：桂林三金 公告编号：2025-017 桂林三金药业股份有限公司 第八届监事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 桂林三金药业股份有限公司（以下简称"公司"）于2025年4月14日以书面 和电子邮件方式向监事发出第八届监事会第九次会议通知，会议于2025年4月24 日在广西壮族自治区桂林市临桂区人民南路9号公司会议室举行。本次会议应出 席会议的监事3人，实际出席会议的监事3人，会议由监事会主席阳忠阳先生主持， 会议召开程序符合《公司法》及《公司章程》的有关规定。 二、监事会会议审议情况 1.审议通过了《2024年年度报告全文及摘要》（同意票3票，反对票0票， 弃权票0票）。 经审核，监事会认为：董事会编制和审核公司《2024年年度报告全文及摘要》 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案需提交公司2024年度股东大会审议。 【详细内容见2025年4月26日《中国证券报》 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-016 2.审议通过了《2024年度董事会工作报告》（同意票9票，反对票0票，弃权 票0票）。 公司独立董事向董事会提交了《2024年度独立董事述职报告》，并将在公司 2024年度股东大会上进行述职。 本议案已经公司董事会审计委员会审议并取得了明确同意的意见，尚需提交 公司2024年度股东大会审议。 桂林三金药业股份有限公司 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林三金药业股份有限公司（以下简称"公司"）于2025年4月14日以书面 和电子邮件方式向董事和监事发出第八届董事会第十三次会议通知，会议于2025 年4月24日在广西壮族自治区桂林市临桂区人民南路9号公司会议室举行。本次会 议应出席会议的董事9人，实际出席会议的董事9人。会议由公司董事长邹洵先生 主持，公司全体监事、高级管理人员列席了会议。会议召开程序符合《公司法》 和《公司章程》的有关规定。 【详细内容见2025年4月26日《中国证券报》《证券时报》《证券日报》及 巨 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-009 桂林三金药业股份有限公司 关于2024年度利润分配方案及2025年中期现金分红 规划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 1.董事会审议情况 桂林三金药业股份有限公司（以下简称"公司"）于2025年4月24日召开第 八届董事会第十三次会议，审议通过了《关于2024年度利润分配方案及2025年中 期现金分红规划的议案》（同意票9票，反对票0票，弃权票0票），并将该议案 提交公司2024年度股东大会审议。 2.监事会审议情况 公司于2025年4月24日召开第八届监事会第九次会议，审议通过了《关于2024 年度利润分配方案及2025年中期现金分红规划的议案》（同意票3票，反对票0 票，弃权票0票）。经审核，监事会认为：该利润分配方案及中期现金分红规划 符合公司经营现状及未来发展规划，符合公司利润分配政策和股东回报规划，在 兼顾公司可持续发展的同时重视股东的合理投资回报，董事会决策程序合法合规， 不存在损害公司和全体股东利益的情形。 3.本议案需提交公司2024年度 ...

| | | | 一、审计报告……………………………………………………… 第 1—5 页 | | --- | | 二、财务报表……………………………………………………… 第 6—13 页 | | （一）合并资产负债表…………………………………………… 第 6 页 | | （二）母公司资产负债表………………………………………… 第 7 页 | | （三）合并利润表………………………………………………… 第 8 页 | | （四）母公司利润表……………………………………………… 第 9 页 | | （五）合并现金流量表……………………………………………第 10 页 | | （六）母公司现金流量表…………………………………………第 11 页 | | （七）合并所有者权益变动表……………………………………第 12 页 | | （八）母公司所有者权益变动表…………………………………第 13 页 | | 三、财务报表附注……………………………………………… 第 14—101 页 | 审 计 报 告 天健审〔2025〕7905 号 桂林三金药业股份有限公司全体股东： 一、审计意见 我们审计了桂林三金药业股份有限公司（以下简称 ...

按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了桂林三金药业股份有限公司（以下简称桂林三金公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是桂林 三金公司董事会的责任。 二、注册会计师的责任 目 录 一、内部控制审计报告………………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕7907 号 桂林三金药业股份有限公司全体股东： 我们认为，桂林三金公司于 2024 年 12 月 31 日按照《企业内部控制基本规 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 方国华 中国·杭州 中国注册会计师： 王剑飞 二〇二五年四月二十四日 第 2 页 共 2 页 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 专项审计说明 天健审〔2025〕7906 号 桂林三金药业股份有限公司全体股东： 我们接受委托，审计了桂林三金药业股份有限公司（以下简称桂林三金公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的桂林三金公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金 往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供桂林三金公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为桂林三金公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解桂林三金公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇总表应当与已审的财务报表一并阅读。 二、管 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥466,571,831.61, a decrease of 3.32% compared to ¥482,586,774.29 in the same period last year[5] - Net profit attributable to shareholders increased by 4.80% to ¥104,816,228.19 from ¥100,017,772.21 year-on-year[5] - The basic earnings per share rose by 5.88% to ¥0.18, up from ¥0.17 in the same period last year[5] - Net profit for the current period is 104,816,228.19, compared to 100,017,772.21 in the previous period, indicating a growth of approximately 3%[21] - Other comprehensive income for the current period is 18,185,554.41, a significant improvement from -9,270,924.95 in the previous period[21] Cash Flow - The net cash flow from operating activities surged by 82.37% to ¥45,690,928.80, compared to ¥25,053,971.39 in the previous year[5] - Cash flow from operating activities decreased to 485,577,611.65 from 505,614,745.70, indicating a decline in cash generation from core operations[22] - Net cash flow from operating activities was $45,690,928.80, an increase from $25,053,971.39 in the previous period, indicating a positive trend in operational efficiency[23] - Net cash flow from financing activities was $65,947,402.45, a recovery from a negative cash flow of $101,543,337.74 in the previous period, showing improved financing conditions[24] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.37% to ¥4,332,605,500.47 from ¥4,232,210,339.05 at the end of the previous year[5] - Total liabilities decreased to 1,199,827,966.86 from 1,222,434,588.04, reflecting a reduction in financial obligations[20] - Non-current liabilities increased to 240,606,597.60 from 226,976,635.54, indicating potential long-term financing strategies[20] - The company’s non-current assets decreased to ¥1,467,746,473.09 from ¥1,667,628,567.53, a decline of about 12%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,526[12] - The largest shareholder, Guilin Sanjin Group, holds 62.07% of shares, totaling 364,679,300 shares[12] - The first phase of the employee stock ownership plan holds 5,147,976 shares, representing 0.88% of total shares[12] Investment Activities - The company reported a 200.82% increase in cash received from investment activities, totaling ¥295,500,000.00, due to the redemption of financial products[10] - Total cash inflow from investment activities reached $599,961,141.23, significantly higher than $274,739,448.15 in the prior period, reflecting strong investment recovery[23] - Cash received from investment recovery was $295,500,000.00, compared to $98,233,131.97 previously, highlighting effective asset management[23] - Cash outflow for investment activities totaled $110,510,744.49, down from $391,146,730.70, suggesting a reduction in capital expenditures[23] Operational Efficiency - The company experienced a 61.43% decrease in cash received from other operating activities, amounting to ¥42,326,408.23, mainly due to reduced cash repayments[9] - The company completed the election of new independent directors, effective from April 13, 2025[14] - Research and development expenses increased to 38,346,676.10 from 33,086,145.88, highlighting a focus on innovation and new product development[20] Equity - The company’s total equity attributable to shareholders increased by 4.09% to ¥3,132,777,533.61 from ¥3,009,775,751.01 at the end of the previous year[5] - The total equity attributable to shareholders increased to 3,132,777,533.61 from 3,009,775,751.01, reflecting a strengthening of the company's financial position[20]

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.19 billion, representing a 1.03% increase compared to ¥2.17 billion in 2023[21]. - Net profit attributable to shareholders for 2024 reached approximately ¥521.53 million, a significant increase of 23.79% from ¥421.30 million in 2023[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥396.25 million, up by 3.64% from ¥382.33 million in 2023[21]. - The basic earnings per share for 2024 was ¥0.89, reflecting a 23.61% increase compared to ¥0.72 in 2023[21]. - The total assets of the company at the end of 2024 were approximately ¥4.23 billion, a 7.52% increase from ¥3.94 billion at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥3.01 billion, which is a 6.84% increase from ¥2.82 billion at the end of 2023[21]. - The net cash flow from operating activities for 2024 was approximately ¥588.33 million, an increase of 7.12% from ¥549.25 million in 2023[21]. - The company's weighted average return on equity for 2024 was 17.62%, up from 14.68% in 2023, indicating improved profitability[21]. Market and Industry Insights - The pharmaceutical manufacturing industry in China achieved a total revenue of 25,298.5 billion CNY in 2024, remaining flat year-on-year, while total profit decreased by 1.1%[32]. - The retail pharmacy market is projected to grow by 3.7% in 2024, with online pharmacies leading this growth at 14.4%[33]. - The online pharmacy market sales reached 758 billion CNY in 2024, reflecting a significant shift in consumer purchasing behavior[33]. - The company ranks 29th in the "Top 100 Chinese Traditional Chinese Medicine Enterprises" and 44th in the "Top 50 Comprehensive Competitiveness of Traditional Chinese Medicine Industry" for 2024[35]. Product Development and Innovation - The company has 47 unique specialty products and 79 valid invention patents, including 1 US invention patent[40]. - The company aims to strengthen its leadership in the throat and urinary health sectors, while also expanding into cardiovascular, neurological, respiratory, and digestive health[39]. - The company is committed to a dual-wing development strategy focusing on traditional Chinese medicine and biopharmaceuticals[39]. - The company launched 17 research projects in 2024, including 6 formal pipeline projects and 5 new drug discovery projects[76]. - The company is advancing multiple R&D projects, including BC006, BC008, and BC007, targeting late-stage solid tumors with ongoing Phase I clinical trials[89]. Regulatory and Compliance - The company acknowledges potential risks including industry policy changes, product price declines, and intensified market competition, urging investors to remain cautious[5]. - The government has implemented multiple policies to support the development of innovative drugs, emphasizing the importance of price management and medical insurance[38]. - The National Medical Insurance Bureau is reforming payment methods to enhance the efficiency of medical insurance fund usage and improve patient experience[37]. Marketing and Sales Strategies - The company has established a comprehensive marketing system across the country, ensuring reliable drug quality and competitive advantages[39]. - The company plans to adopt new marketing models to enhance brand competitiveness and promote products at the terminal level[120]. - The establishment of a specialized sales department aims to enhance market penetration of key products in the medical field, driving new sales growth points[124]. Shareholder Engagement and Governance - The company has implemented a cash dividend policy, having executed two cash dividends during the reporting period, demonstrating a commitment to returning value to shareholders[143]. - The governance structure of the company has been continuously improved, adhering to relevant laws and regulations, ensuring compliance with the standards set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[143]. - The company has established a shareholder communication mechanism to ensure that all shareholders, especially minority shareholders, are informed and can participate in decision-making processes[143]. Risk Management - The company acknowledges the long and uncertain drug development cycle, which is influenced by various factors, including technology, approval processes, and market competition, leading to risks in innovation and new product development failures[134]. - To mitigate R&D risks, the company will strengthen its R&D team, enhance the innovation system, and improve the evaluation mechanism throughout the R&D process, focusing on the transformation of R&D results in the biopharmaceutical sector[134]. - The company faces risks from intensified market competition due to centralized procurement and dynamic adjustments in the medical insurance catalog[130]. Employee and Operational Insights - The total number of employees at the end of the reporting period is 2,567, with 1,808 in the parent company and 759 in major subsidiaries[177]. - The company has 637 production staff, 1,022 sales personnel, and 555 technical staff, indicating a diverse workforce[177]. - The average training hours per employee in 2024 is 31.63 hours, with a total of 60,445.37 training hours planned[179]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting a revenue growth of 20%[138]. - The company is focusing on market expansion in Southeast Asia, targeting a 10% market share by the end of 2024[138]. - The company plans to enhance its digital marketing strategy, aiming for a 25% increase in online sales[138].

证券代码：002275 证券简称：桂林三金 公告编号：2025-006 桂林三金药业股份有限公司 关于独立董事取得独立董事培训证明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称"公司"）分别于2025年3月26日召 开第八届董事会第十二次会议、2025年4月11日召开2025年第一次临时股东大会， 审议通过了《关于补选公司第八届董事会独立董事的议案》，选举胡余嘉先生为 公司第八届董事会独立董事，并选举其担任公司第八届董事会审计委员会委员， 任期自2025年4月13日起至第八届董事会届满之日止。 （www.cninfo.com.cn）披露的《桂林三金药业股份有限公司独立董事候选人关 于参加独立董事培训并取得独立董事资格证书的承诺书》。 近日，公司收到独立董事胡余嘉先生的通知，其已经按照相关规定参加了深 圳证券交易所举办的上市公司独立董事任前培训（线上），并取得由深圳证券交 易所创业企业培训中心颁发的《上市公司独立董事培训证明》。 特此公告。 桂林三金药业股份有限公司 董 事 会 2025 年 4 月 24 日 截至20 ...

证券代码：002275 证券简称：桂林三金 编号：2025-005 桂林三金药业股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1.本次股东大会未出现否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、 会议召开情况 1.召开时间： （1）现场会议召开时间：2025年4月11日15:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年4 月11日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年4月11日9:15-15:00 期间的任意时间。 2.现场会议召开地点：广西壮族自治区桂林市临桂区人民南路9号公司四楼 会议室 3.召开方式：现场投票与网络投票相结合的方式 4.召集人：公司董事会 5.主持人：董事长邹洵先生 6.公司已于2025年3月27日在《中国证券报》《证券时报》《证券日报》及 巨潮资讯网发布了《关于召开2025年第 ...